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The efficacy of cidofovir in juvenile recurrent respiratory papillomatosis (JRRP) remains uncertain 
due to the lack of published case-control studies. 
Aim: To establish factors affecting the progression of JRRP prognosis, and to evaluate cidofovir for 
eradicating JRRP. 
Study Design: Retrospective. 
Methods: 22 children with JRRP were evaluated at a referral center. All children underwent surgical 
debulking, followed by cidofovir injection (Group 2) or not (Group 1). Age at diagnosis was correlated 
with the Derkay score and disease outcome. Disease progression was compared between groups 
1 and 2. 
Results: fifteen children were considered disease-free; 8 were in Group 2 and 7 in Group 1. Age and 
total and clinical scores (P<0.05) were negatively correlated. The mean number of surgeries required 
to control the disease was identical in both groups; the duration of treatment until remission was 
significantly higher in Group 1 (P<0,05). 
Conclusion: JRRP is more aggressive in earlier onset disease. The duration of treatment was 
significantly lower in patients treated with cidofovir until eradication of JRRP compared to patients 
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INTRODUCTION
Juvenile recurrent respiratory papillomatosis 
(JRRP) is the most common benign tumor of the larynx 
and the second main cause of dysphonia in children. 
The incidence of JRRP has been estimated at 4.3 new 
cases for every 1,000 children in the United States of 
America.1 JRRP is caused by the human papilloma virus 
(HPV); the subtypes 6 and 11 have been reported as 
being most frequently associated with recurrent respi-
ratory papillomatosis1-4 in the pediatric population. The 
main form of transmission in children is vertical, during 
pregnancy.1 Recurrent respiratory papillomatosis affects 
mostly primiparous children of young mothers in normal 
delivery.1,2,4
JRRP is a benign disease, but has an unfavorable 
prognosis because of frequent relapses and dissemination 
across the aerodigestive tract; there is also the risk of 
malignant degeneration.4 There is a 3.6 higher chance 
of requiring over four surgeries per year, and a nearly 
twofold chance of the disease involving more than one 
anatomical site, when the diagnosis is made before 
age 3 years.5 Other poor prognostic factors of JRRP are 
subglottic extension and tracheostomy.6
The current therapy for JRRP is surgery, either 
using laser or the microdebrider. As no approach can 
eradicate JRRP, the main goal of surgery is to remove 
lesions at the same time preserving adjacent anatomical 
structures1 to avoid synechiae or stenoses. However, 
papillomas recur rapidly in some patients and require 
more than four surgeries per year; or they may present 
disease in multiple sites.1 In these cases, adjuvant therapy 
is indicated in an attempt to improve the outcome.
Intralesional injection of cidofovir (Vistide®, Gile-
ad, Foster City, CA, US) has been encouraged by several 
case series of recurring JRRP, although the dose has not 
been standardized. Cidofovir is the most frequently used 
adjuvant treatment for this condition in the US;1 accor-
ding to reviews by the American Society of Pediatric 
Otorhinolaryngology (ASPO) and the British Association 
of Pediatric Otorhinolaryngology (BAPO), about 10% of 
JRRP patients are given adjuvant therapy with cidofovir.7
The purpose of this study was to evaluate the 
effect of age on the diagnosis and the extent of disease 
on the progression of JRRP, and to assess what effect 
cidofovir has on eradication of JRRP. Children treated 
successfully with surgery alone were compared with chil-
dren treated successfully with surgery and intralesional 
injection of cidofovir.
MATERIALS AND METHODS
Before 2006, two disciplines carried out identical 
laryngeal surgeries at our institution, namely the otorhi-
nolaryngology and the head & neck surgery clinics; they 
are currently joining efforts and reviewing their approach 
of laryngeal surgery.
The otorhinolaryngology team proposed cidofovir 
as a treatment option after the hospital approved the 
purchase of this drug for the treatment of JRRP in 2003. 
At present, all children with JRRP treated at this hospital 
are given adjuvant cidofovir therapy. Because of cost, 
this drug has been approved only for the otorhinolaryn-
gology unit; the head & neck surgery unit offers only 
surgery. This bias has generated two groups treating 
JRRP differently; one group systematically is treated with 
cidofovir, and the other is not, therefore comprising a 
control group for this study.
Thus, we carried out a retrospective study of 
22 pediatric patients undergoing removal of laryngeal 
papillomas from 2000 to 2008. Only patients in whom 
symptoms and lesions regressed fully for at least 6 mon-
ths as evaluated on laryngeal endoscopy. Patients lost 
to follow-up, or where records were insufficient for this 
study, or patients with residual disease were excluded. 
Children in both groups underwent laryngeal surgery 
under general anesthesia for removal of papillomas; 
apparently tumor-free neighboring structures were pre-
served. In the adjuvant therapy group, cidofovir was 
injected after surgical hemostasis.
The Derkay1 scale was applied in each procedure 
to classify the lesions and the severity of JRRP. Group 
1 patients (control) underwent further surgeries when 
symptoms manifested; group 2 children (treated with 
cidofovir) systematically underwent a second surgery one 
month after the first procedure to reinject the drug, even 
if there are no signs of recurrences. Next, these children 
were reassessed every 15 to 30 days; surgery was done 
if there were any signs of recurrences, with or without 
symptoms. As cidofovir was injected at longer intervals 
than those reported in the literature, a 15 mg/mL con-
centration was used, within the maximum dose of 1 mg/
kg of weight. Only two surgeons performed all cidofovir 
injections. Renal and hepatic function, coagulation and a 
complete blood count were evaluated periodically; thus 
far, no disorders have been documented.
The age at diagnosis of JRRP was correlated with: 
1) disease aggressiveness according to the Derkay1 clini-
cal, anatomical and total scales; 2) tendency to recur in 
relation to the moment of treatment and the number of 
surgeries required for controlling the lesions. Spearman’s 
correlation test was applied to calculate these correla-
tions, which were defined as significant when p<0.05.
The progression of both treatment groups was 
compared in terms of the total number of surgeries per 
patient and the duration of treatment. The mean inter-
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val between surgeries and Derkay’s mean total score in 
each surgery (except for the diagnostic procedure) were 
compared for a better description of groups. The Mann-
Whitney non-parametric test was applied to analyze these 
parameters; the significance level was p<0.05.
The hospital institutional review board approved 
this study (process no. 11227/2008).
RESULTS
The sample consisted of 22 patients, 12 female 
and 10 male. The age at diagnosis ranged from 10 to 99 
months (mean: 45.59 ± 23.96). The initial clinical score 
ranged from 1 to 11 points (mean: 5.18 ± 3.36). Dys-
phonia was the most common symptom; it was present 
in all 22 patients, and was moderately intense in 17 
patients. Stridor was present in 10 cases, 5 with at least 
moderate intensity.
The most commonly affected site are the vocal 
folds (20 of 22 cases; bilateral in 15 cases), followed 
by the vestibular folds (15 cases, bilateral in 10 cases). 
The anterior commissure (11 cases) and the subglottis 
(8 cases) were also affected, albeit less frequently. The 
mean anatomical score was 10.5 ± 5.11, and the mean 
total score was 15.68 ± 7.08.
These scores were correlated with age of diagno-
sis; there was a significant negative correlation between 
age and the clinical/total scores (r = -0.4413 / r = -0.4349; 
p<0.05 for both). Age of diagnosis and the anatomical 
score (r = -0.3922; p=0.07) trended towards a negative 
correlation (Fig. 1). However, there was no correlation 
between age at diagnosis and the number of surgeries or 
the required duration of treatment for disease remission.
Before the comparison between treatment groups, 
7 patients were excluded; 4 were lost to follow-up and 
3 still had active lesions upon evaluation. There were 15 
patients in this phase of the study, 7 in group 1 (surgical 
treatment only) and 8 in group 2 (surgical treatment 
following by cidofovir injection). Table 1 shows the data 
on each group.
The mean number of surgeries needed to con-
trol the disease was similar in both groups (6.71 ± 4.71 
in group 1 and 6.50 ± 3.96 in group 2, p>0.05). But 
the duration of treatment until disease remission was 
significantly higher in group 1 (50.71 ± 35.16 months) 
compared to group 2 (20 ± 15.97 months) (p<0.05). 
This difference occurred because the interval between 
surgeries was significantly shorter in group 2 (3.42 ± 1.65 
months) compared to group 1 (11.62 ± 10.96 months) 
(p<0.05), as was the mean total score during surgeries 
for recurrence (5.42 ± 2.30 in group 2 vs. 13.22 ± 3.75 
in group 1; p<0.001).
Figure 1. Correlation between age at diagnosis and the Derkay score: 
1a: clinical score; 1b: anatomical score; 1c: total score.
Table 1. Comparison of treated groups; group 1 was the control and 
group 2 consisted of patients treated with cidofovir. Statistical com-
parison based on the Mann-Whitney no-parametric test.
 Group 1 Group 2
  Mean SD Mean SD P
Number of 
surgeries
6.71 4.71 6.50 3.96 > 0.9999
Duration of 
treatment
50.71 35.16 20.00 15.97 0.0440
Interval between 
surgeries
11.62 10.96 3.42 1.65 0.0289
Mean total score 13.22 3.75 5.42 2.30 0.0006
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DISCUSSION
JRRP is generally diagnosed before the age 5 
years; the age distribution at this point is equal.4 Our 
results concur with other published data. The mean age 
at diagnosis was 45 months and the gender distribution 
was similar.
The main site of papillomas was the vocal folds, 
followed by the vestibular folds and subglottic exten-
sion. Thus, dysphonia was the most common symptom, 
followed by stridor. Five of these children required 
tracheostomy during treatment; 3 were in the cidofovir 
group and 2 were in the control group. Decannulation 
was successful after disease control in all cases.
No papillomatous extension to the trachea or 
beyond the respiratory tract was seen in our study sam-
ples, probably because of the inclusion criteria for this 
retrospective study; only children with disease remission 
for at least 6 months (considered successfully treated ca-
ses) were included. Although this criterion was important 
for comparing treatment protocols, it obviously resulted 
in a bias by excluding children with more extensive 
disease (and therefore a worse outcome).
JRRP is more aggressive - more respiratory symp-
toms and disease extension - the lower the patient’s age. 
This concurs with other published results.1 However, 
more extensive disease was not necessarily related with 
increased difficulty in disease remission; no significant 
correlation was found between age and disease extension 
and the duration of treatment.
The surgical technique was similar in both groups; 
micro-scissors or cutting forceps only were used. Laser or 
microdebriders were not used in any of these patients. 
There was a difference in the indication of surgery if 
the disease recurred: surgery was indicated for any si-
zed tumor in the cidofovir group, whereas surgery was 
done in the control group only if there were symptoms 
(dysphonia or breathing difficulty). Thus, more surgeries 
at shorter intervals and more limited lesions after each 
procedure were expected in the cidofovir group. In fact, 
the mean interval between surgeries and the Derkay 
mean score during these procedures were significantly 
lower in the cidofovir-treated group. Nevertheless, the 
mean number of procedures required to control JRRP was 
similar in both group. The treatment time for eradication 
of JRRP was significantly lower in the cidofovir-treated 
group compared to controls.
Our results suggest that cidofovir-treated children 
have a better prognosis compared to those treated sur-
gically only; the duration of treatment until eradication 
of JRRP was shorter in the former. These results concur 
with recently published studies,1,3-5 in particular with 
Chadha et al.’s7 review, which suggested that cidofovir 
may in fact be an adjuvant treatment for JRRP.
At this point only one double-blind randomized 
study of cidofovir for the treatment of JRRP has been 
published;8 however, if included adult and pediatric 
patients. Furthermore, because of FDC requirements, 
the initial dose in that study was 0.75 mg/mL in adults 
and 0.3 mg/mL in children, which was rather different 
than the routinely recommended doses in the literature. 
Under such conditions, the authors found no differences 
between the cidofovir-treated group and controls.
The study protocol differs from others in the 
literature in that, for logistical issues, we were unable 
to carry out surgeries every two weeks in all patients 
in the cidofovir protocol. This situation required us to 
carry out periodical assessments, and surgeries were 
indicated based on the results of laryngeal endoscopy. 
Thus, the study group was more similar to the control 
group, and a truer comparison of certain variables that 
would not have been evaluated in more usual protocols 
in published studies became possible.
On the whole it was not possible to state that the 
superior results of group 2 were due to the use of cidofo-
vir, since this group was not matched to the control group 
in relation to treatment interval or indication of surgery 
for recurrences. The study was also not randomized or 
double-blind. However, ours results suggest that in chil-
dren with JRRP who progressed favorably, cidofovir was 
an import adjuvant co-factor to the traditional surgery; 
it decreased the treatment time for disease remission.
CONCLUSION
We may conclude that:
- JRRP is more aggressive (on symptoms and di-
seases extension) the younger the child at the moment 
of diagnosis.
- Patients treated with cidofovir had a significantly 
lower duration of treatment until eradication of JRRP 
compared to the group treated surgically only.
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